Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Esomeprazole for Initial Symptoms of Erosive Esophagitis
NCT06720610Phase 4Not yet recruiting
- Sponsor
- Universitas Indonesia
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vonoprazan in erosive esophagitis (EE) (2 arms), sponsored by Universitas Indonesia. Primary endpoint: Number of Participants with Symptoms Resolution of Erosive Esophagitis at 14 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT06720610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720610.